Latest News and Press Releases

Wegovy® injection is the first GLP-1 weight-loss treatment approved for 48-hour controlled-temperature delivery in the EU

Metabo Drops claims evaluated: 2026 report on coffee metabolism drop ingredients, proprietary blend dosages, pricing, and label disclosures.

US FDA has approved Wegovy® HD (once-weekly injectable semaglutide 7.2 mg) to reduce excess body weight and maintain weight reduction long-term.

Dublin, March 05, 2026 (GLOBE NEWSWIRE) -- The "Weight Loss Market Key Players Analysis, Product Innovations, Strategic Alliances, Brand Strategies, and Market Share Forecasts" report has been added...

QuickBurn BHB exogenous ketone supplement: ingredients, BHB salt research, side effects, ketosis claims, and what to verify before buying.

Dublin, Feb. 20, 2026 (GLOBE NEWSWIRE) -- The "Weight Loss and Diet Management Market Report 2026" has been added to ResearchAndMarkets.com's offering. The weight loss and diet management...

Dublin, Feb. 20, 2026 (GLOBE NEWSWIRE) -- The "Weight Management Supplements Market Report 2026" has been added to ResearchAndMarkets.com's offering. The weight management supplements market is...

Final EU approval of high-maintenance dose of Wegovy. The new dose gives healthcare professionals even more flexibility to tailor treatment.

Kailera and Hengrui report positive topline data from Hengrui’s Phase 2 clinical trial of oral ribupatide, a GLP-1/GIP receptor dual agonist peptide.

Cheapest Compounded Semaglutide without insurance 2026: What low-cost GLP-1 pricing often excludes from total monthly cost—consumer framework.